Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,444 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pharmacodynamics Clear all

Conditions: Wound Healing
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL343, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 3 more

Conditions: Hematologic Malignancies, Nonmalignant Diseases, Immune Deficiency, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
Interventions: Thiotepa; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Polycythemia Vera
Interventions: Bomedemstat; Drug
Lead sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Plantation, Florida • Skokie, Illinois • Ann Arbor, Michigan + 5 more

Conditions: Parkinson's Disease
Interventions: CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, Rytary 145 mg; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 8 more

Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions: EDI200; Drug
Lead sponsor: Edimer Pharmaceuticals; Industry
Eligibility: 48 Hours to 14 Days · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri

Conditions: Alport Syndrome
Interventions: RG012; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: La Mesa, California • Los Angeles, California • Riverside, California + 4 more

Conditions: CAH - Congenital Adrenal Hyperplasia
Interventions: NBI-74788; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more

Conditions: Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
Interventions: MYK-491, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more

Conditions: Atherosclerosis
Interventions: LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Chronic Idiopathic Constipation
Interventions: SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 14
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more

Conditions: Cardiovascular Disease
Interventions: INS50589 Intravenous Infusion; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cannabis Toxicology
Interventions: Cannabis; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Interventions: belinostat, Paclitaxel, Carboplatin; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 7
States / cities: Newport Beach, California • Orlando, Florida • Covington, Louisiana + 4 more

Conditions: Multiple Sclerosis
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Latham, New York

Conditions: Overweight, Obesity
Interventions: NNC0247-0829, Placebo (NNC0247-0829); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Subjects
Interventions: placebo, lorazepam, GW876008; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more

Conditions: Hereditary Angioedema
Interventions: STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV); Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 557, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more

Conditions: Healthy
Interventions: TLL018 tablet, placebo; Drug
Lead sponsor: TLL Pharmaceutical, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Acute Myeloid Leukemia
Interventions: Crenolanib, Sorafenib, methotrexate, hydrocortisone and cytarabine with leucovorin; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 39 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy
Interventions: ALXN1007, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: STGD1, Stargardt Disease 1
Interventions: Tinlarebant, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 12 Years to 20 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more

Search by objective public record fields.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

A Study of RG-012 in Subjects With Alport Syndrome

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

A Study of STAR-0215 in Healthy Adult Participants

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease